During the Hepatitis C Antiviral Long-term Treatment against Cirrhosis Trial, 3.5 years of maintenance peginterferon-alfa-2a therapy did not affect liver fi brosis progression or clinical outcomes among 1,050 previous interferon nonresponders with advanced fi brosis or cirrhosis. We investigated whether reduced hepatic infl ammation was associated with clinical benefi t in 834 patients with a baseline and follow-up biopsy 1.5 years after randomization to peginterferon or observation.
INTRODUCTION
Treatment with pegylated interferon-alfa plus ribavirin cures 40 -50 % of persons with chronic hepatitis C. Th e remaining patients have persistent viremia and the potential for progressive hepatic infl ammation and fi brosis ( 1 ) . Although some patients with untreated chronic hepatitis C may have nonprogressive liver disease, insidious progression to cirrhosis occurs in at least 20 -25 % of patients over 2 decades, increasing the risk for hepatic decompensation, hepatocellular carcinoma, and liver-related death ( 2 ) .
Th e achievement of a sustained virological response (SVR), i.e., the absence of detectable hepatitis C virus (HCV) RNA for at least 24 weeks following a course of antiviral therapy, is associated with a marked reduction in the incidence of end-stage liver disease and its consequences of decompensated liver disease and death ( 3 ) . Even in the absence of SVR, 40 -75 % of treated patients have been reported to achieve histological benefi t from interferon-based therapy ( 4, 5 ) . In a key study, investigators analyzed 53 patients with a wide range of liver fi brosis who exhibited reduction of HCV RNA levels (but not SVR) and improvement in hepatic infl ammation during an initial course of interferon monotherapy. Among these patients, 2 years of additional maintenance therapy was associated with continued suppression of hepatic necroinfl ammatory activity but not with signifi cantly reduced fi brosis progression ( 6 ) .
Th ese early observations provided the rationale for the prospective, multicenter Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial. Th e primary goal of the HALT-C Trial was to determine whether 3.5 years of treatment with half-dose maintenance peginterferon-alfa therapy could prevent fi brosis progression and / or the development of hepatic decompensation and other clinical outcomes in previous interferon nonresponders with advanced hepatic fi brosis (Ishak fi brosis score ≥ 3). Our intention-to-treat analysis of the 1,050 patients enrolled in the HALT-C Trial indicated that maintenance peginterferon treatment did not yield clinical benefi t ( 7 ) . In a recent sub-analysis of this cohort, however, we demonstrated that patients with ≥ 4 log 10 virological suppression during full-dose peginterferon / ribavirin lead-in therapy had fewer clinical outcomes over the 3.5 years aft er randomization compared to those without such profound virological suppression ( 8 ) . In the current analysis, we investigated the relationship between peginterferon / ribavirin-induced virological suppression and changes in hepatic infl ammation based on serial liver biopsies separated by 1.5 and 3.5 years in this large cohort of patients with advanced liver disease. Furthermore, we evaluated improvement in hepatic infl ammation as a potential mechanism by which reduced alanine aminotransferase (ALT) levels, hepatic fi brosis progression, and clinical outcomes (up to 8.5 years) could have occurred in a subset of HALT-C Trial patients.
METHODS

Patients and study design
Th e design ( 9 ) and results ( 7 ) of the HALT-C Trial have been described. Th e current analysis was limited to 834 HALT-C participants who had baseline and follow-up liver biopsies at year 1.5 (per protocol) and were randomized to receive either half-dose peginterferon therapy (90 μ g / week) or no treatment for 3.5 years. Th irteen patients who had follow-up biopsies but no HCV RNA measurements, or were randomized to observation but received peginterferon outside of the study, or were randomized to halfdose peginterferon and received full-dose interferon or ribavirin were also excluded. Patients had bridging fi brosis (Ishak fi brosis stage 3 -4) or cirrhosis (Ishak fi brosis stage 5 -6) on a screening liver biopsy (baseline). Of the 834 patients in this analysis, 657 were treated with full-dose, standard-of-care peginterferonalfa-2a (180 μ g / week) and ribavirin (1,000 -1,200 mg / day) during a " lead-in " phase of the HALT-C Trial. Patients with HCV RNA undetectable by PCR assay (Roche COBAS Amplicor HCV Test, v. 2.0) at treatment week 20 were defi ned as responders and received a total of 48 weeks of full-dose peginterferon / ribavirin treatment with follow-up monitoring through week 72. SVR was defi ned as HCV RNA undetectable by PCR at week 72. All week 20 responders who experienced subsequent virological breakthrough during or relapse aft er peginterferon / ribavirin therapy were off ered randomization into the main 3.5-year HALT-C Trial, and randomization occurred at a median of 26 weeks (range ~ 7 to 61 weeks) aft er viral relapse. Nonresponders, defi ned as patients with PCRdetectable HCV RNA levels at week 20 of lead-in therapy, were randomized to half-dose peginterferon or observation at week 24. Aft er 3.5 years of treatment or observation, continuation of follow-up every 6 months was off ered to all patients through October, 2009 (median follow-up of 6 years, range 0 -8.5 years).
Clinical and other laboratory data were collected from all patients according to standard procedures and intervals described below ( 9 ) . Th e Institutional Review Boards of all participating institutions approved the study protocols, and written informed consent was obtained before participation from all study patients.
Testing for HCV RNA and serum ALT levels
Serum samples were frozen at − 80 ° C at each clinical site, then shipped on dry ice, and tested in real time at the University of Washington Virology Laboratory with both the quantitative Roche COBAS Amplicor HCV Monitor Test, v. 2.0 assay (lower limit of detection 600 IU / ml) and, if negative, by the Roche COBAS Amplicor HCV Test, v. 2.0 assay (or PCR assay, lower limit of detection 100 IU / ml) as described previously ( 10, 11 ) . HCV genotypes were determined with the INNO-LiPA HCV II kit (Siemens Medical Solutions Diagnostics, Tarrytown, NY).
Patients were classifi ed into groups according to changes in their HCV RNA levels during the lead-in phase and aft er randomization. Th e mean of screening and pretreatment log 10 HCV RNA levels was used as the baseline value. Log 10 changes from baseline to week 20 (during the lead-in phase) were calculated by subtracting the level at week 20 from baseline. Change in HCV RNA during the fi rst 1.5 years aft er randomization was calculated by subtracting the mean of the levels at 0.5, 1.0, and 1.5 years aft er randomization from baseline. Both were classifi ed as < 2, 2 -< 4, and ≥ 4 log 10 changes, as previously described ( 8 ) . To calculate these means, we assigned HCV RNA-negative results by the qualitative Roche COBAS Amplicor HCV Test a log 10 value of 2.00 (100 IU / ml), and HCV RNA-negative results by the quantitative Roche COBAS Amplicor HCV Monitor Test but positive by the more sensitive qualitative Roche COBAS Amplicor HCV Test a log 10 value of 2.78 (600 IU / ml).
Serum ALT levels, tested at each clinical site every 3 months, are expressed as ALT divided by the upper limit of normal. Th e baseline value was the mean of the screening and pretreatment ALT levels. Percent ALT change was calculated with the following formula: ((mean ALT between year 0.5 and year 1.5 − mean baseline ALT) / mean baseline ALT) × 100 % . ALT improvement was defi ned as an ALT decrease by > 25 % , ALT worsening was defi ned as an ALT increase by > 25 % , and patients with no change in ALT were those with an ALT change ≤ 25 % of baseline. Th e percent ALT change for years 0.5 -3.0 was calculated with a similar formula. Year 3.0 was used instead of 3.5 because many patients stopped their interferon treatment between years 3.0 and 3.5.
Liver histology
All patients underwent screening liver biopsy (baseline) within 12 months before enrollment. All biopsy specimens were assigned a consensus histological score by a team of 11 hepatopathologists. Both infl ammatory (modifi ed hepatic activity index, (HAI)) and fi brosis scoring were based upon the criteria of Ishak et al. ( 12 ) . Follow-up biopsies were performed at 1.5 and 3.5 years aft er randomization. Change in hepatic infl ammation or fi brosis was defi ned as a ≥ 2-point increase (worse) or ≥ 2-point decrease (improved) at 1.5 or 3.5 years aft er randomization when compared with the baseline biopsy score.
Defi nition of clinical and fi brosis outcomes
Clinical outcomes for all patients were defi ned prospectively as hepatic decompensation (bleeding esophageal varices, ascites, spontaneous bacterial peritonitis, or hepatic encephalopathy) ( 13 ) , an increase in the Child -Turcotte -Pugh score to ≥ 7 ( 14 ) on two consecutive study visits 3 months apart, hepatocellular carcinoma ( 15 ), or death from any cause. For patients with bridging fi brosis (Ishak fi brosis score of 3 or 4) at study entry, an additional criterion for disease progression (fi brosis outcome) was a ≥ 2-point increase in the Ishak score at the time of the year-1.5 or -3.5 liver biopsies.
Statistical analyses
We used SAS (Statistical Analysis Soft ware, Cary, NC) version 9.1. for statistical analyses. Baseline variables in the control or peginterferon groups were compared by chi-square or t -test. Th e Mantel -Haentszel chi-square test for trend was used for 2 × 3 tables of improvement in one variable vs. ordered categories in the other. We used logistic regression for the analysis of predictors of improvement in HAI and ALT. To evaluate the change in mean ALT from baseline to the mean of the values at years 0.5 -1.5 and 0.5 -3.0, we used analysis of variance adjusting for baseline variables. We applied Kaplan -Meier estimates of the clinical outcome rates at 7 years and Cox proportional hazards regression analyses, stratifi ed by the presence of cirrhosis at baseline, to assess the eff ect of changes in HCV RNA during the lead-in phase and the eff ect of changes from baseline in hepatic infl ammation and ALT on clinical outcomes. Hazard ratios (HRs) and 95 % confi dence intervals are reported. Th e Cox regression analyses included the entire follow-up period, from randomization through 8.5 years or October 20, 2009, whichever occurred fi rst. Forty patients with outcomes before the year − 1.5 biopsy were excluded because they did not have the year − 1.5 biopsy, but 18 patients with outcomes before year 1.5 were included. Analyses were performed for both the treatment groups combined, including treatment group as a predictor variable, and separately by treatment group. In most instances, the latter analysis is reported because diff erences in HAI and ALT between the treatment groups might confound the association of improvement with other variables. We did not adjust for multiple comparisons. For analyses that compared more than three groups, we reported either the overall P -value or, as specifi ed, the P -value for a trend across the three groups.
RESULTS
Characteristics of the study cohort
All patients in this analysis were required to have had a year-1.5 liver biopsy. Table 1 shows the baseline clinical, demographic, laboratory, and histological characteristics of this cohort ( N = 834) according to treatment status. Patients in the treatment group were older and more likely to have HCV genotype 1 infection, but the diff erences were small. Compares the distribution of all three subsets (nonresponders, breakthrough / relapsers, and express patients) between the control and treated groups. Express patients received full-dose peginterferon / ribavirin therapy outside of the HALT-C Trial before enrollment ( 7 ) . All values represent means ( ± s.d.) unless otherwise indicated.
LIVER Liver Inflammation and Disease Progression
Although our previous intention-to-treat analysis of 1,050 HALT-C Trial patients demonstrated no clinical benefi t of maintenance peginterferon treatment, we reported modest but statistically signifi cant reductions in hepatic infl ammation (HAI), and serum ALT and HCV RNA levels in treated patients ( 7 ) . Figure 1 shows, by treatment group, the frequency of patients who experienced improvement, no change, or worsening of HAI on their year-1.5 biopsy compared with baseline as well as changes in serum ALT to year 1.5 compared with baseline. For all analyses involving histological liver infl ammation, we chose to focus mainly on the year-1.5 results ( N = 834; N = 414 control and N = 420 treated) because the sample size was substantially smaller at year 3.5 ( N = 652); however, the analyses of the year-3.5 data were consistent with those found at year 1.5, as discussed below.
Th e mean change in HAI from baseline to year 1.5 was 0.12 (95 % CI − 0.12 to 0.35) in the control group and − 0.87 (95 % CI − 1.10 to − 0.64) in the treated group ( P < 0.0001 for control vs. treated). Th e signifi cant diff erence between the control and treated groups involved three of the four components of the HAI ( 12 ) (parenchymal injury P < 0.0001, periportal infl ammation P < 0.0001, and portal infl ammation P = 0.002). Th e fourth component, confl uent necrosis, could not be analyzed because only one patient had any necrosis scored on the year-1.5 biopsy. Similar results were found for the change to year 3.5.
Relationships between HCV RNA suppression and hepatic infl ammation and serum ALT levels
Th e majority of patients in this analysis underwent lead-in treatment with full-dose peginterferon / ribavirin therapy immediately preceding randomization to maintenance peginterferon or observation ( N = 657). To investigate the relationships between virological suppression and improvement in hepatic infl ammation and / or ALT levels, we analyzed HAI improvement according to randomization status and the degree of HCV RNA suppression at week 20 of lead-in therapy ( Figure 2a ). A higher proportion of patients with improved HAI had greater reduction in HCV RNA levels during the preceding lead-in phase in both the control ( P < 0.0001) and treated groups ( P < 0.0001). Th is fi nding was also refl ected in greater mean HAI improvement according to greater HCV RNA level reduction. A substantial proportion of patients in both the treated and control groups (31 -53 % ), including those with maximal virological suppression ( ≥ 4 log 10 ) during lead-in treatment (31 and 40 % ), demonstrated no change in hepatic infl ammation on the year-1.5 biopsy. Other patients experienced worsening of hepatic infl ammation in both the control (19 -32 % ) and peginterferon (5 -23 % ) groups. Worth noting, HCV RNA levels in 94 % of control-group patients and 57 % of treated-group patients were within 0.5 log 10 of baseline levels by year 0.5 (6 months aft er completion of lead-in therapy); moreover, HCV viremia persisted at this level through collection of the year-1.5 and -3.5 biopsies.
A larger reduction in HCV RNA levels during lead-in treatment was also associated with improvement in serum ALT between years 0.5 and 1.5 aft er randomization compared with baseline ( Figure 2b ) in both the control ( P < 0.0001) and treated groups ( P = 0.0002). Virological response to peginterferon / ribavirin treatment during lead-in for patients included in Figure 2 was associated with expected clinical and demographic factors, as previously published ( 11 ) and shown in Supplementary Tables 1 and 2 online.
Among the 516 lead-in patients who had biopsy results at both year 1.5 and year 3.5, virological suppression during lead-in treatment was signifi cantly associated with improvement of hepatic infl ammation on the year-3.5 biopsy in both the control and treated groups ( P = 0.01 and P = 0.001, respectively). Th e mean (SE) changes in HAI at year 3.5 were 0.16 (0.23), 0.33 (0.37), and − 0.82 (0.33) in the control group ( P = 0.03) and − 0.64 (0.22), − 1.05 (0.34), and − 2.23 (0.30) in the treated group ( P = 0.0002) for HCV RNA decreases of < 2, 2 -< 4, and ≥ 4 log 10 , respectively. Similarly, greater HCV RNA reduction during lead-in treatment was associated with a more substantial reduction in ALT levels between years suppression exhibited the greatest improvement in HAI and ALT ( Figure 3 ). Specifi cally, the 54 patients who were able to maintain ≥ 2 log 10 suppression of HCV RNA levels during both lead-in and randomized phases ( Figure 3a , third column) were more likely to have improved HAI (74 % ) compared with the remaining 274 patients who had less virological suppression during the same time period (31 % , P < 0.0001, Figure 3a , columns 1 and 2). Similarly, the same 54 patients who maintained ≥ 2 log 10 suppression of HCV RNA levels during both lead-in and randomized phases were more likely to have improved ALT (54 % ) than the 274 patients who had less virological suppression (34 % , P = 0.007). Clinical and demographic information for patients included in Figure 3 0.5 and 3.0 of the study in both the randomized control and treated groups ( P < 0.0001 and P = 0.0003, respectively). shown on the y-axis and by the numbers in the columns. The mean change in ALT and associated s.e. for the group of patients represented by each column is shown below the x-axis. Percent ALT change was calculated as described for Figure 1 . P values are based on a chi-square test for trend in the percent improved. The number of patients represented by each column are as follows : peginterferon / ribavirin (PEG-RBV) / control groups < 2 log 10 reduction n = 185, 2 to < 4 log 10 reduction n = 66, ≥ 4 log 10 reduction n = 78; PEG-RBV / PEG groups < 2 log 10 reduction n = 175, 2 to < 4 log 10 reduction n = 68, ≥ 4 log 10 reduction n = 85. 
Relationship between improvement in hepatic infl ammation and serum ALT
Th e relationship between improved serum ALT and hepatic infl ammation is shown in Figure 4 . Patients with improved HAI had signifi cantly greater improvement in mean ALT than patients without improved HAI in both the control and treated groups ( P < 0.0001 both groups). Similar results were found when ALT data through year 3 and the year-3.5 HAI were evaluated ( P = 0.004 in the control group and P = 0.02 in the treated group).
Relationship between hepatic infl ammation and histological fi brosis progression
We reported previously that virological suppression during the lead-in or randomized phases of the HALT-C Trial did not infl uence fi brosis progression (data not shown) ( 8 ) . Here we explored the relationship between HAI change and fi brosis progression in the same biopsies among patients with Ishak fi brosis scores of 3 and 4 at study entry ( Figure 5 ). Patients with Ishak fi brosis stages 5 and 6 were excluded from this analysis because they could not progress by ≥ 2 points. Th e majority of patients (71 -84 % ) demonstrated no change from baseline to year 1.5 in their fi brosis scores ( Figure 5a ). Fibrosis progression was signifi cantly associated with change in hepatic infl ammation in both the control and treated groups ( P for trend = 0.02 and 0.0003). In the control group, fi brosis progression occurred in 26 % with worse HAI, in 13 % with unchanged HAI, and in 11 % with improved HAI. In the group randomized to maintenance peginterferon therapy, fi brosis progression occurred in 29 % with worse HAI, in 18 % with unchanged HAI, and in only 7 % with improved HAI. Th e odds ratios for the association between improved HAI and fi brosis progression were 0.55, 95 % CI 0.23 -1.32, P = 0.18 in the control group and 0.27, 95 % CI 0.12 -0.65, P = 0.003 in the treated group. Mean changes in the Ishak fi brosis score also refl ected the association between HAI improvement and lack of fi brosis progression. Th e relationship between improved HAI and reduced fi brosis progression was also evident on the year-3.5 biopsy ( Figure 5b , P = 0.01 and 0.0001 in the control and treated groups, respectively). The mean change in Ishak fi brosis score and associated s.e. for each group of patients represented by a column is shown below the x-axis. Improved HAI was associated with less fi brosis progression in the same biopsy at years 1.5 and 3.5 in both the control ( P = 0.02 and 0.01 respectively) and treatment groups ( P = 0.0003 and 0.0001), based on separate analyses for each group. P values are based on a chi-square test for trend in the percentage with fi brosis progression. The number of patients represented by each column are as follows: ( a ) change in HAI to year 1.5 / control groups worse n = 73, same n = 114, improved n = 64; change in HAI to year 1.5 / PEG-IFN groups worse n = 48, same n = 111, improved n = 101; ( b ) change in HAI to year 3.5 / control groups worse n = 65, same n = 85, improved n = 61; change in HAI to year 3.5 / PEG-IFN groups worse n = 32, same n = 89, improved n = 95. IFN, interferon; PEG, pegylated.
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( P = 0.08). When analyzed separately by the treatment group, we found that the trend towards signifi cance was present in the control group ( P = 0.07) but not in the treated group ( P = 0.44).
Improvement in hepatic infl ammation and serum ALT and relationships with clinical outcomes
We evaluated whether improvement in hepatic infl ammation and / or ALT was associated with the occurrence of predefi ned clinical outcomes (hepatic decompensation, hepatocellular carcinoma, or death) during follow-up to 8.5 years. Fewer clinical outcomes occurred in patients with improved hepatic infl ammation compared to patients without improved infl ammation at year 1.5, regardless of whether patients were randomized to the control (HR 0.60, 95 % CI 0.36 -0.99, P = 0.05) or treated groups (HR 0.63, 95 % CI 0.41 -0.95, P = 0.03) ( Figure 6a ). Maintenance therapy had no impact on reducing clinical outcomes ( P = 0.67), as reported previously ( 7 ). We also examined the relationship between ALT change to year 1.5 and clinical outcomes ( Figure 6b ). Fewer patients with year-1.5 improvement in ALT had clinical outcomes compared to patients without improvement in ALT in the control group (HR We analyzed changes in infl ammation and fi brosis in the same biopsies at year 1.5 ( Figure 5a ) or year 3.5 ( Figure 5b ). However, we also investigated whether improved HAI on the year-1.5 biopsy was associated with reduced fi brosis progression on the year-3.5 biopsy or on either the year-1.5 or year-3.5 biopsies considered together. In both cases, the association between improved HAI and reduced fi brosis progression held, with overall odds ratios of 0.54 (95 % CI 0.32 -0.92, P = 0.02, N = 427) and 0.52 (95 % CI 0.33 -0.81, P = 0.004, N = 511), respectively (the control and treated groups combined). In this analysis, no relationship was found between the treatment group and fi brosis progression. As previously reported for the full cohort ( 7 ), no signifi cant eff ect of half-dose maintenance peginterferon therapy on fi brosis progression was found at either year 1.5 ( P = 0.77) or year 3.5 ( P = 0.78).
In the patient subgroup with cirrhosis (Ishak stages 5 and 6) at baseline, we found a trend towards improvement in hepatic fi brosis by ≥ 2 points among patients with reduced hepatic infl ammation by ≥ 2 points (fi brosis improved in 15 % with worse HAI, in 21 % with unchanged HAI, and in 26 % with improved HAI); however, the sample sizes were relatively small ( N = 61, 156, and 106, respectively), and the trend fell short of statistical signifi cance For panel a , sample sizes in the control group were hepatic activity index (HAI) worse ( n = 109), HAI same ( n = 203), and HAI improved ( n = 102); and in the treated group were HAI worse ( n = 73), HAI same ( n = 178), and HAI improved ( n = 169). For panel b , sample sizes in the control group were ALT worse ( n = 61), ALT same ( n = 248), and ALT improved ( n = 105); and in the treated group were ALT worse ( n = 73), ALT same ( n = 200), and ALT improved ( n = 147). P values for differences among the three groups were derived from a Cox regression analysis for the control and treated groups evaluated separately.
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Liver Inflammation and Disease Progression 0.56, 95 % CI 0.34 -0.91, P = 0.02) but not in the treated group (HR 0.85, CI 0.57 -1.28, P = 0.44). Consistent with our earlier report up to year 3.5 ( 8 ), maximal virological suppression ( ≥ 4 log 10 ) during lead-in treatment was associated with fewer clinical outcomes to year 8.5 in both the control (HR 0.50, 95 % CI 0.27 -0.92, P = 0.03) and treated groups (HR 0.37, 95 % CI 0.18 -0.73, P = 0.004). When HAI change and week 20 lead-in virological suppression ( < 2 log 10 vs. ≥ 2 log 10 ) were analyzed in multivariate Cox regressions for the control and treated groups combined, both HAI improvement (HR 0.67, 95 % CI 0.47 -0.98, P = 0.04) and virological suppression during the lead-in (HR 0.57, 95 % CI 0.42 -0.79, P = 0.001) were associated with reduced clinical outcomes. However, when ALT improvement and week-20 lead-in virological suppression were both analyzed as predictors of outcomes, only virological suppression remained a signifi cant predictor of outcomes. Th e 54 patients with persistent virological suppression ≥ 2 log 10 during both the lead-in and randomized phases had fewer clinical outcomes compared to those with virological suppression < 2 log 10 during lead-in or ≥ 2 log 10 during the leadin phase and < 2 log 10 during the randomized phase ( P = 0.007). Finally, when both HAI improvement and ALT improvement were included in a Cox regression analysis for prediction of clinical outcomes, the HR for HAI improvement remained statistically significant (HR 0.64, 95 % CI 0.46 -0.89, P = 0.007), but the HR for ALT improvement was no longer statistically signifi cant (HR 0.79, 95 % CI 0.58 -1.08, P = 0.14).
DISCUSSION
Our previous intention-to-treat analysis of the HALT-C Trial demonstrated no eff ect of long-term half-dose maintenance peginterferon treatment on the occurrence of clinical outcomes and fi brosis progression in 1,050 previous interferon nonresponders with advanced hepatic fi brosis ( 7 ) . Th e current post-hoc analysis of a subset of HALT-C Trial patients expands and extends early observations on the impact of interferon-induced reduction of hepatic infl ammation on fi brosis progression ( 6 ) owing to our focus on patients with advanced hepatic fi brosis, the measurement of clinical outcomes, the long duration of the follow-up period (up to 8.5 years), and the large sample size. We report that improved hepatic infl ammation was associated with marked reductions in serum HCV RNA during the preceding 24-week lead-in phase of fulldose peginterferon / ribavirin treatment. Th us, improved hepatic infl ammation in subsets of both the maintenance peginterferon and control groups could be explained by the fact that all of these patients were pretreated with full-dose peginterferon / ribavirin. Patients with profound virological suppression during the leadin phase who were also able to maintain substantially suppressed viral levels during the randomized half-dose maintenance phase were most likely to experience improvement in hepatic infl ammation. Most importantly, improved infl ammation was associated with fewer clinical outcomes and less fi brosis progression compared to patients without such improvement.
We previously showed that maximal suppression of HCV RNA levels ( ≥ 4 log 10 ) during lead-in therapy was the most important variable associated with a reduced frequency of subsequent clinical decompensation outcomes, although no direct relationship was found between HCV RNA suppression and histological fi brosis progression ( 8 ) . Here we report that HCV RNA suppression during lead-in therapy was associated with reduction of hepatic infl ammation and, separately, reduced hepatic infl ammation was associated with less fi brosis progression. Overall, these data confi rm the close association between HCV RNA levels and hepatic infl ammation and suggest that amelioration of these factors is crucial to limiting liver disease progression ( 6, 16 ) .
Th e eff ect of virological suppression during lead-in therapy on reduction of hepatic infl ammation appeared to be surprisingly durable even in patients with subsequent viral recrudescence, as reduced hepatic infl ammation was found in a subset of patients randomized to the untreated-control group as long as 3.5 years aft er the cessation of peginterferon / ribavirin treatment. Th is observation confi rms the notion that peginterferon therapy has two distinct eff ects that may be separable: (1) reduction of viremia and (2) long-term reduction of hepatic infl ammation. Th is clinical observation is consistent with the many reports of the direct eff ects of interferon-alfa on viral replication ( 17 ) , distinct from eff ects on proinfl ammatory lymphocyte function ( 18 ) and on inhibition of collagen production by hepatic stellate cells ( 19 ) .
What could be the biological basis for the durability of the reduced hepatic infl ammation induced by peginterferon / ribavirin treatment? Th e reduction in the hepatic infl ammatory cell infi ltrate and of hepatocyte death as documented in the year-1.5 and year-3.5 HAI scores, even with viral recurrence to near baseline levels, suggests the possibility that peginterferon / ribavirin may have had durable epigenetic molecular eff ect(s) on cells within the liver that have a role in liver infl ammation. Whatever these eff ects might have been, peginterferon / ribavirin clearly had direct or indirect (downstream) eff ects on lymphocyte recruitment and activity in the liver, as indicated by reductions in portal and periportal infl ammation and parenchymal injury in the HAI scores. Future detailed studies of liver samples from patients who experience maximal HCV RNA suppression will be necessary to determine what durable molecular events could account for the post-treatment eff ects we describe.
Worth emphasizing is the observation that the HALT-C Trial was dominated by patients who were null (virological) responders -who experienced < 2 log 10 HCV RNA reduction with fulldose peginterferon / ribavirin lead-in treatment ( Figure 2 , N = 360 of 657). By contrast, most patients in this analysis with improved hepatic infl ammation derived from the subset with profound virological suppression ( ≥ 4 log 10 ) by week 20 of lead-in therapy who experienced subsequent virological breakthrough during or relapse aft er up to 24 more weeks of full-dose peginterferon / ribavirin treatment compared with the true nonresponders. Whether such profound and mostly sustained virological suppression ( ≥ 4 log 10 ) by peginterferon / ribavirin treatment in this small subset was related to common host or viral characteristics among these patients is not known. Our fi ndings are consistent with the possibilities that virological suppression can result in reduction of hepatic infl ammation, that virological suppression serves as a marker of persons more likely to reduce hepatic infl ammation as a consequence of treatment, or both. Moreover, our data are consistent with the notion that patients who can achieve profound virological suppression and reduction of hepatic infl ammation may have the potential to benefi t from longer-term pharmacological suppression of HCV replication. On the other hand, we also identifi ed a potential cost of maintenance peginterferon therapy: almost 50 % of patients who experienced worsening of hepatic infl ammation with therapy had clinical outcomes ( Figure 6a ). Although the increased infl ammation may have been a marker for those destined to have a poor outcome rather than a result of maintenance interferon therapy, these latter fi ndings support our previous conclusion that the use of long-term interferon maintenance therapy in HCV-infected nonresponder patients with advanced liver disease cannot be recommended at this time.
Our fi ndings may help to explain why we were unable to demonstrate clinical benefi t of maintenance peginterferon among the 1,050 patients enrolled in the overall HALT-C Trial. Th e majority of patients were true null virological responders with a < 2 log 10 decrease of HCV RNA during full-dose peginterferon / ribavirin therapy. Among these patients, few demonstrated improvement of hepatic infl ammation, most demonstrated no change, and some demonstrated worsening infl ammation during therapy. During subsequent randomized-phase treatment with half-dose peginterferon, the vast majority of patients exhibited < 2 log 10 virological suppression and relatively few patients experienced substantial virological suppression ( 7 ). Th us, based upon the data presented here and elsewhere ( 8 ) , if virological suppression is required for clinical benefi t to occur, then we speculate that the degree of virological suppression with half-dose peginterferon therapy during the maintenance phase was insuffi cient to reduce hepatic infl ammation and clinical and fi brosis outcomes in the entire treated group. Alternatively, the durable histological impact of short-term virological suppression during lead-in therapy might have had an overwhelming, confounding eff ect that might have obscured a diff erence in fi brosis progression and clinical outcomes between the randomized control and maintenance-peginterferon groups in the HALT-C Trial.
In conclusion, analysis of laboratory data and paired serial liver biopsies from a subset of well-pedigreed patients with advanced hepatic fi brosis enrolled in the HALT-C Trial demonstrates the associations between peginterferon / ribavirin-induced virological suppression, hepatic infl ammation, serum ALT levels, hepatic fi brosis progression, and liver disease outcomes (of hepatic decompensation, liver cancer, and death). Although maximal virological suppression during the lead-in phase of the Trial was shown to have no direct impact on fi brosis progression ( 8 ) , profound suppression of HCV RNA, achieved in a small minority of patients, was found to be associated with decreased hepatic infl ammation. Decreased hepatic infl ammation, in turn, appeared to be a critical factor that was associated with reduced fi brosis progression and, to a lesser extent, fewer clinical outcomes. Th e surprisingly durable benefi cial eff ect of peginterferon / ribavirin (3.5 years later) on hepatic infl ammation was also associated with a sustained improvement of ALT, despite viral recrudescence at the time of repeat biopsy and serum laboratory measurements. Of note, these results also suggest potential benefi t for patients with advanced liver disease currently being
